Carboprost methyl

InformationUNC0379 UNC0379 is a selective, substrate competitive inhibitor of N-lysine methyltransferase SETD8 with IC50 of 7.9 μM, high selectivity over 15 other methyltransferases.TargetsSETD8 (Cell-free assay) 7.3 μMIn vitroUNC0379 is competitive

InformationUNC0379 UNC0379 is a selective, substrate competitive inhibitor of N-lysine methyltransferase SETD8 with IC50 of 7.9 μM, high selectivity over 15 other methyltransferases.TargetsSETD8 (Cell-free assay) 7.3 μMIn vitroUNC0379 is competitive

InformationUNC0379 UNC0379 is a selective, substrate competitive inhibitor of N-lysine methyltransferase SETD8 with IC50 of 7.9 μM, high selectivity over 15 other methyltransferases.TargetsSETD8 (Cell-free assay) 7.3 μMIn vitroUNC0379 is competitive

InformationUNC0379 UNC0379 is a selective, substrate competitive inhibitor of N-lysine methyltransferase SETD8 with IC50 of 7.9 μM, high selectivity over 15 other methyltransferases.TargetsSETD8 (Cell-free assay) 7.3 μMIn vitroUNC0379 is competitive

VT02956 is a LATS inhibitor ( IC 50 : 0.76 nM for LATS1, 0.52 nM for LATS2). VT02956 targets the Hippo pathway. VT02956 inhibits ESR1 expression and growth of ER+ breast cancer cell lines and patient-derived tumor organoids.IC50&amp: Target:IC50:

VT02956 is a LATS inhibitor ( IC 50 : 0.76 nM for LATS1, 0.52 nM for LATS2). VT02956 targets the Hippo pathway. VT02956 inhibits ESR1 expression and growth of ER+ breast cancer cell lines and patient-derived tumor organoids.IC50&amp: Target:IC50:

VU 0365114 is a selective mAChR M5 positive allosteric modulator, with an EC50 of 2.7 μM, and &gt:30 μM for M1, M2, M3 and M4 receptors. VU 0365114 increases insulin secretion stimulated by ACh in human β-cells.

VU 0365114 is a selective mAChR M5 positive allosteric modulator, with an EC50 of 2.7 μM, and &gt:30 μM for M1, M2, M3 and M4 receptors. VU 0365114 increases insulin secretion stimulated by ACh in human β-cells.

VU 0365114 is a selective mAChR M5 positive allosteric modulator, with an EC50 of 2.7 μM, and &gt:30 μM for M1, M2, M3 and M4 receptors. VU 0365114 increases insulin secretion stimulated by ACh in human β-cells.

VU 0365114 is a selective mAChR M5 positive allosteric modulator, with an EC50 of 2.7 μM, and &gt:30 μM for M1, M2, M3 and M4 receptors. VU 0365114 increases insulin secretion stimulated by ACh in human β-cells.

VU 0365114 is a selective mAChR M5 positive allosteric modulator, with an EC50 of 2.7 μM, and &gt:30 μM for M1, M2, M3 and M4 receptors. VU 0365114 increases insulin secretion stimulated by ACh in human β-cells.

VU 0365114 is a selective mAChR M5 positive allosteric modulator, with an EC50 of 2.7 μM, and &gt:30 μM for M1, M2, M3 and M4 receptors. VU 0365114 increases insulin secretion stimulated by ACh in human β-cells.